1 – 9 of 9
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States : A comparative study of accelerated approvals
(
- Contribution to journal › Article
- 2022
-
Mark
The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity
(
- Contribution to journal › Article
-
Mark
Sedation in specialized palliative care : A cross-sectional study
(
- Contribution to journal › Article
- 2019
-
Mark
ABC transporters as cancer drivers : Potential functions in cancer development
(
- Contribution to journal › Scientific review
- 2015
-
Mark
Targeted immunotherapies overtaking emerging oncology market value based growth
(
- Contribution to journal › Letter
- 2001
-
Mark
The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of chemotherapy effects in some major tumour types--summary and conclusions
(
- Contribution to journal › Scientific review
- 1995
-
Mark
Navoban (tropisetron) alone and in combination with dexamethasone in the prevention of chemotherapy-induced nausea and vomiting : the Nordic experience. The Nordic Antiemetic Trial Group
(
- Contribution to journal › Article
- 1994
-
Mark
Tropisetron (Navoban) in the prevention of chemotherapy-induced nausea and vomiting--the Nordic experience
(
- Contribution to journal › Article
-
Mark
A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis
(
- Contribution to journal › Article